Glycyrrhizin Enhances the Proliferation of Diabetic Bone Marrow-derived Mesenchymal Stem Cells: A Potential Therapeutic Agent in Endodontic Surgery
Mohamed Ahmed Gomaa, Yousry Mahmoud Elhawary, Amany E. Badr
Abstract
Aim: This study aimed to evaluate the effects of glycyrrhizin, as a potential therapeutic agent in endodontic surgery, on the proliferation and viability of diabetic human bone marrow-derived mesenchymal stem cells (hBM-MSCs).Materials and methods: Diabetic human bone marrow-derived mesenchymal stem cells (hBM-MSCs) were isolated and characterized by flow cytometry.The cells were treated with different concentrations of Glycyrrhizin (Gly) (12.5, 25, 50, and 100 g/mL) and 0.1% dimethyl sulfoxide (DMSO) as the control group.MTT assay was performed to evaluate the cell proliferation and viability after 24, 48, and 72 hours of the cell treatment with Gly.The optical density (OD) was measured at 570 nm.Each assay was repeated three times.The corrected OD and cell viability were determined.ANOVA followed by the Bonferroni post hoc test evaluated the statistical significance at p < 0.05.Results: Flow cytometric analysis of the isolated cells showed positive expression of mesenchymal markers (CD105 and CD90) and negative expression of hematopoietic markers (CD34 and CD14).After 24 and 48 hours of cell treatment, Gly in 100 g/mL concentration significantly decreased the diabetic hBM-MSC proliferation as compared with the control (p < 0.05).Gly in 12.5-50 g/mL concentrations significantly increased the cell proliferation after 72 hours of treatment as compared with the control (p < 0.05).The diabetic hBM-MSC proliferation and viability at 12.5-50 g/mL concentrations were significantly greater than that at 100 g/mL concentration (p < 0.05). Conclusion:Under the present study conditions, Gly (in 12.5-50 g/mL concentrations) did not show cytotoxicity to diabetic hBM-MSCs and enhanced their proliferation.Gly may represent a potential therapeutic agent in endodontic surgery in diabetic patients.Clinical significance: Preclinical assessment of Gly effects on diabetic hBM-MSCs is important for determining its effective concentration range, anticipating its therapeutic potential, and designing future in vivo studies.